Stock VIVE VIVESTO AB
Add to a list
To use this feature you must be a member
Log inSign up

Financials Vivesto AB

Equities

VIVE

SE0000722365

Pharmaceuticals

Market Closed - Nasdaq Stockholm
Other stock markets
 11:24:43 2024-04-26 am EDT 		5-day change 1st Jan Change
0.285 SEK -1.55% Intraday chart for Vivesto AB -9.52% -30.06%
Mar. 26 Transcript : Vivesto AB - Special Call
Mar. 07 Vivesto AB Doses First Patient in its Clinical Paccal Vet Trial CI

Valuation

Fiscal Period: December 2017 2018 2019 2020 2021 2022
Capitalization 1 462.2 1,835 1,856 1,847 1,176 233.5
Enterprise Value (EV) 1 602.9 2,006 1,880 1,651 1,089 99.17
P/E ratio -1.85 x -12.9 x -3.97 x -8.78 x -8.86 x -0.6 x
Yield - - - - - -
Capitalization / Revenue 64.2 x 149 x 178 x 465 x 40.7 x 76.8 x
EV / Revenue 83.8 x 163 x 181 x 416 x 37.7 x 32.6 x
EV / EBITDA -4.43 x -20 x -15.5 x -9.21 x -8.81 x -0.76 x
EV / FCF -8.3 x -13.4 x -41.9 x -35.8 x -18.8 x -2.46 x
FCF Yield -12.1% -7.46% -2.39% -2.79% -5.31% -40.7%
Price to Book 1.1 x 4.68 x 2.37 x 2.72 x 2.14 x 0.72 x
Nbr of stocks (in thousands) 176,406 200,524 448,370 448,370 448,370 538,043
Reference price 2 2.620 9.150 4.140 4.120 2.623 0.4340
Announcement Date 7/7/17 9/14/18 9/5/19 4/29/21 4/28/22 4/25/23
1SEK in Million2SEK
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2017 2018 2019 2020 2021 2022
Net sales 1 7.195 12.33 10.41 3.972 28.87 3.04
EBITDA 1 -136.2 -100.4 -121.1 -179.3 -123.6 -130.1
EBIT 1 -140.7 -105.2 -126.3 -182.9 -128.8 -135
Operating Margin -1,955.29% -853.33% -1,213.43% -4,605.32% -446.32% -4,441.38%
Earnings before Tax (EBT) 1 -160.2 -118 -169.1 -210.4 -132.7 -356.7
Net income 1 -160.2 -118 -201.9 -210.4 -132.7 -356.7
Net margin -2,227.14% -957.38% -1,939.16% -5,297.21% -459.75% -11,734.18%
EPS 2 -1.418 -0.7100 -1.044 -0.4693 -0.2960 -0.7233
Free Cash Flow 1 -72.67 -149.6 -44.88 -46.09 -57.85 -40.39
FCF margin -1,009.99% -1,213.97% -431.1% -1,160.35% -200.4% -1,328.68%
FCF Conversion (EBITDA) - - - - - -
FCF Conversion (Net income) - - - - - -
Dividend per Share - - - - - -
Announcement Date 7/7/17 9/14/18 9/5/19 4/29/21 4/28/22 4/25/23
1SEK in Million2SEK
Estimates

Balance Sheet Analysis

Fiscal Period: December 2017 2018 2019 2020 2021 2022
Net Debt 1 141 172 23.3 - - -
Net Cash position 1 - - - 197 86.8 134
Leverage (Debt/EBITDA) -1.033 x -1.71 x -0.1923 x - - -
Free Cash Flow 1 -72.7 -150 -44.9 -46.1 -57.9 -40.4
ROE (net income / shareholders' equity) -51.2% -36.6% -54.7% -1.75% -21.6% -81.5%
ROA (Net income/ Total Assets) -17% -12.1% -13.4% -1.8% -11% -17.8%
Assets 1 945.1 978 1,512 11,660 1,201 2,008
Book Value Per Share 2 2.380 1.960 1.750 1.520 1.230 0.6000
Cash Flow per Share 2 0.2200 0.0900 0.5200 0.0900 0.0200 0.0200
Capex 1 0.52 0.42 2.5 6.55 1.11 0.28
Capex / Sales 7.16% 3.37% 23.97% 164.88% 3.86% 9.11%
Announcement Date 7/7/17 9/14/18 9/5/19 4/29/21 4/28/22 4/25/23
1SEK in Million2SEK
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Annual profits - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

1st Jan change Capi.
VIVESTO AB Stock Vivesto AB
-30.06% 13.99M
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+25.83% 661B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+27.00% 566B
JOHNSON & JOHNSON Stock Johnson & Johnson
-6.76% 352B
MERCK & CO., INC. Stock Merck & Co., Inc.
+20.34% 332B
ABBVIE INC. Stock AbbVie Inc.
+3.00% 283B
ASTRAZENECA PLC Stock AstraZeneca PLC
+13.09% 231B
NOVARTIS AG Stock Novartis AG
+5.46% 200B
ROCHE HOLDING AG Stock Roche Holding AG
-9.61% 195B
AMGEN INC. Stock Amgen Inc.
-6.26% 145B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. VIVE Stock
  4. Financials Vivesto AB